Imperial College London

ProfessorJonathanWeber

Faculty of MedicineFaculty of Medicine Centre

Dean of the Faculty of Medicine
 
 
 
//

Contact

 

+44 (0)20 7594 3905j.weber

 
 
//

Assistant

 

Mrs Siobhan Pigott +44 (0)20 7594 3901

 
//

Location

 

2.15Faculty BuildingSouth Kensington Campus

//

Summary

 

Publications

Publication Type
Year
to

286 results found

Viegas EO, Kroidl A, Munseri PJ, Missanga M, Nilsson C, Tembe N, Bauer A, Joachim A, Joseph S, Mann P, Geldmacher C, Fleck S, Stohr W, Scarlatti G, Aboud S, Bakari M, Maboko L, Hoelscher M, Wahren B, Robb ML, Weber J, McCormack S, Biberfeld G, Jani I, Sandstrom E, Lyamuya Eet al., 2018, Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design, PLOS ONE, Vol: 13, ISSN: 1932-6203

JOURNAL ARTICLE

Stirrup OT, Dunn DT, Tostevin A, Sabin CA, Pozniak A, Asboe D, Cox A, Orkin C, Martin F, Cane P, UK HIV Drug Resistance Database, UK Collaborative HIV Cohortet al., 2018, Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data., AIDS Res Ther, Vol: 15

BACKGROUND: The prevalence of HIV-1 resistance to antiretroviral therapies (ART) has declined in high-income countries over recent years, but drug resistance remains a substantial concern in many low and middle-income countries. The Q151M and T69 insertion (T69i) resistance mutations in the viral reverse transcriptase gene can reduce susceptibility to all nucleoside/tide analogue reverse transcriptase inhibitors, motivating the present study to investigate the risk factors and outcomes associated with these mutations. METHODS: We considered all data in the UK HIV Drug Resistance Database for blood samples obtained in the period 1997-2014. Where available, treatment history and patient outcomes were obtained through linkage to the UK Collaborative HIV Cohort study. A matched case-control approach was used to assess risk factors associated with the appearance of each of the mutations in ART-experienced patients, and survival analysis was used to investigate factors associated with viral suppression. A further analysis using matched controls was performed to investigate the impact of each mutation on survival. RESULTS: A total of 180 patients with Q151M mutation and 85 with T69i mutation were identified, almost entirely from before 2006. Occurrence of both the Q151M and T69i mutations was strongly associated with cumulative period of virological failure while on ART, and for Q151M there was a particular positive association with use of stavudine and negative association with use of boosted-protease inhibitors. Subsequent viral suppression was negatively associated with viral load at sequencing for both mutations, and for Q151M we found a negative association with didanosine use but a positive association with boosted-protease inhibitor use. The results obtained in these analyses were also consistent with potentially large associations with other drugs. Analyses were inconclusive regarding associations between the mutations and mortality, but mortality was high for pati

JOURNAL ARTICLE

Quinn K, Traboni C, Penchala SD, Bouliotis G, Doyle N, Libri V, Khoo S, Ashby D, Weber J, Nicosia A, Cortese R, Pessi A, Winston Aet al., 2017, A first-in-human study of the novel HIV-fusion inhibitor C34-PEG(4)-Chol, SCIENTIFIC REPORTS, Vol: 7, ISSN: 2045-2322

JOURNAL ARTICLE

Smit E, White E, Clark D, Churchill D, Zhang H, Collins S, Pillay D, Sabin C, Nelson M, Winston A, Jose S, Tostevin A, Dunn DTet al., 2017, An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs, JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, Vol: 72, Pages: 2075-2082, ISSN: 0305-7453

JOURNAL ARTICLE

Joseph S, Quinn K, Greenwood A, Cope AV, McKay PF, Hayes PJ, Kopycinski JT, Gilmour J, Miller AN, Geldmacher C, Nadai Y, Ahmed MIM, Montefiori DC, Dally L, Bouliotis G, Lewis DJM, Tatoud R, Wagner R, Esteban M, Shattock RJ, McCormack S, Weber Jet al., 2017, A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes, FRONTIERS IN IMMUNOLOGY, Vol: 8, ISSN: 1664-3224

JOURNAL ARTICLE

Joseph S, Quinn K, Greenwood A, Miller A, Cope AV, Mckay PF, Hayes P, Kopycinski J, Bouliotis G, Gilmour J, McFarlane L, Tatoud R, Shattock RJ, Lewis D, Montefiore D, Esteban M, Wagner R, McCormack S, Weber Jet al., 2016, UK HVC 003: A Phase I Clinical Trial Exploring a Strategy to Maximise HIV Antibody Responses using Subtype C DNA, MVA and GLA Adjuvanted gp140, Conference on HIV Research for Prevention (HIV R4P), Publisher: MARY ANN LIEBERT, INC, Pages: 99-99, ISSN: 0889-2229

CONFERENCE PAPER

Thornhill J, Inshaw J, Kaleebu P, Cooper D, Ramjee G, Schechter M, Tambussi G, Fox J, Samuel M, Miro JM, Weber J, Porter K, Fidler Set al., 2016, Enhanced Normalization of CD4/CD8 Ratio With Earlier Antiretroviral Therapy at Primary HIV Infection, JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, Vol: 73, Pages: 69-73, ISSN: 1525-4135

JOURNAL ARTICLE

Herath S, Le Heron A, Colloca S, Patterson S, Tatoud R, Weber J, Dickson Get al., 2016, Strain-dependent and distinctive T-cell responses to HIV antigens following immunisation of mice with differing chimpanzee adenovirus vaccine vectors, VACCINE, Vol: 34, Pages: 4378-4385, ISSN: 0264-410X

JOURNAL ARTICLE

Hoffmann M, Pantazis N, Martin GE, Hickling S, Hurst J, Meyerowitz J, Willberg CB, Robinson N, Brown H, Fisher M, Kinloch S, Babiker A, Weber J, Nwokolo N, Fox J, Fidler S, Phillips R, Frater Jet al., 2016, Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection, PLOS PATHOGENS, Vol: 12, ISSN: 1553-7366

JOURNAL ARTICLE

Martin GE, Pantazis N, Hoffmann M, Hickling S, Hurst J, Meyerowitz J, Willberg CB, Robinson N, Brown H, Fisher M, Kinloch S, Babiker A, Weber J, Nwokolo N, Fox J, Fidler S, Phillips R, Frater Jet al., 2016, Exhaustion of activated CD8 T cells predicts disease progression in primary HIV-1 infection, JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, Vol: 19, ISSN: 1758-2652

JOURNAL ARTICLE

Joachim A, Bauer A, Joseph S, Geldmacher C, Munseri PJ, Aboud S, Missanga M, Mann P, Wahren B, Ferrari G, Polonis VR, Robb ML, Weber J, Tatoud R, Maboko L, Hoelscher M, Lyamuya EF, Biberfeld G, Sandstrom E, Kroidl A, Bakari M, Nilsson C, McCormack Set al., 2016, Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial, PLOS ONE, Vol: 11, ISSN: 1932-6203

JOURNAL ARTICLE

Jose S, Quinn K, Dunn D, Cox A, Sabin C, Fidler Set al., 2016, Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation, HIV MEDICINE, Vol: 17, Pages: 368-372, ISSN: 1464-2662

JOURNAL ARTICLE

Quinn K, Bouliotis G, Doyle N, Winston A, Ashby D, Weber J, Libri V, Amara A, Back D, Penchala SD, Khoo S, Nelson M, Jones R, Cortese R, Pessi Aet al., 2016, A first-in-human study, in HIV-positive men, of the novel HIV-fusion inhibitor C34-PEG4-Chol, Publisher: WILEY-BLACKWELL, Pages: 18-18, ISSN: 1464-2662

CONFERENCE PAPER

May MT, Gill MJ, Wittkop L, Klein M, Sabin C, Harrigan PR, Dunn D, Vehreschild JJ, Rubio R, Mocroft A, Cavassini M, Reiss P, Monforte AD, Zangerle R, Ingle SM, Hill T, Jose S, Sterne JAC, Boulle A, Stephan C, Miro JM, Cavassini M, Chene G-V, Costagliola D, Dabis F, Monforte AD, del Amo J, Van Sighem A, Vehreschild J, Gill J, Guest J, Haerry DH-U, Hogg R, Justice A, Mocroft A, Obel N, Crane H, Smith C, Reiss P, Saag M, Sterling T, Teira R, Williams M, Zangerle R, Sterne J, May M, Ingle S, Trickey A, Ainsworth J, Anderson J, Babiker A, Chadwick D, Delpech V, Dunn D, Fisher M, Gazzard B, Gilson R, Hay P, Gompels M, Hill T, Johnson M, Jose S, Kegg S, Leen C, Mackie N, Nelson M, Orkin C, Palfreeman A, Phillips A, Pillay D, Post F, Sabin C, Sachikonye M, Schwenk A, Walsh J, Thornton A, Huntington S, Glabay A, Orkin C, Garrett N, Lynch J, Hand J, de Souza C, Fisher M, Perry N, Tilbury S, Youssef E, Churchill D, Gazzard B, Nelson M, Waxman M, Asboe D, Mandalia S, Anderson J, Munshi S, Awosika D, Post F, Korat H, Taylor C, Gleisner Z, Ibrahim F, Campbell L, Babiker A, Dunn D, Glabay A, Chadwick D, Baillie K, Cope E, Gibney M, Gibson J, Gilson R, Brima N, Williams I, Ainsworth J, Schwenk A, Miller S, Wood C, Johnson M, Youle M, Lampe F, Smith C, Chaloner C, Hill T, Huntington S, Jose S, Phillips A, Sabin C, Thornton A, Walsh J, Mackie N, Winston A, Weber J, Ramzan F, Carder M, Leen C, Wilson A, Morris S, Gompels M, Allan S, Palfreeman A, Moore A, Fox L, Bojanowski J, Lewszuk A, Kegg S, Main P, Mitchell D, Hunter D, Sachikonye M, Hay P, Dhillon M, Martin F, Douglas S, Russell-Sharp Set al., 2016, Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis, AIDS, Vol: 30, Pages: 503-513, ISSN: 0269-9370

JOURNAL ARTICLE

Herath S, Le Heron A, Colloca S, Bergin P, Patterson S, Weber J, Tatoud R, Dickson Get al., 2015, Analysis of T cell responses to chimpanzee adenovirus vectors encoding HIV gag-pol-nef antigen, VACCINE, Vol: 33, Pages: 7283-7289, ISSN: 0264-410X

JOURNAL ARTICLE

Hurst J, Hoffmann M, Pace M, Williams JP, Thornhill J, Hamlyn E, Meyerowitz J, Willberg C, Koelsch KK, Robinson N, Brown H, Fisher M, Kinloch S, Cooper DA, Schechter M, Tambussi G, Fidler S, Babiker A, Weber J, Kelleher AD, Phillips RE, Frater Jet al., 2015, Immunological biomarkers predict HIV-1 viral rebound after treatment interruption, NATURE COMMUNICATIONS, Vol: 6, ISSN: 2041-1723

JOURNAL ARTICLE

Hoehn KB, Gall A, Bashford-Rogers R, Fidler SJ, Kaye S, Weber JN, McClure MO, Kellam P, Pybus OGet al., 2015, Dynamics of immunoglobulin sequence diversity in HIV-1 infected individuals, PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, Vol: 370, ISSN: 0962-8436

JOURNAL ARTICLE

Hamlyn E, Stoehr W, Cooper DA, Fisher M, Tambussi G, Schechter M, Miro JM, Vanobberghen F, Babiker A, Weber J, Mcclure M, Porter K, Fidler Set al., 2015, The effect of short-course antiretroviral therapy initiated in primary HIV-1 infection on interleukin-6 and D-dimer levels, AIDS, Vol: 29, Pages: 1355-1361, ISSN: 0269-9370

JOURNAL ARTICLE

Huntington S, Thorne C, Newell M-L, Anderson J, Taylor GP, Pillay D, Hill T, Tookey PA, Sabin Cet al., 2015, Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy, AIDS, Vol: 29, Pages: 801-809, ISSN: 0269-9370

JOURNAL ARTICLE

Knudsen ML, Ljungberg K, Tatoud R, Weber J, Esteban M, Liljestrom Pet al., 2015, Alphavirus Replicon DNA Expressing HIV Antigens Is an Excellent Prime for Boosting with Recombinant Modified Vaccinia Ankara (MVA) or with HIV gp140 Protein Antigen, PLOS ONE, Vol: 10, ISSN: 1932-6203

JOURNAL ARTICLE

Roberts HE, Hurst J, Robinson N, Brown H, Flanagan P, Vass L, Fidler S, Weber J, Babiker A, Phillips RE, McLean AR, Frater Jet al., 2015, Structured Observations Reveal Slow HIV-1 CTL Escape, PLOS GENETICS, Vol: 11, ISSN: 1553-7390

JOURNAL ARTICLE

White PJ, Fox J, Weber J, Fidler S, Ward Het al., 2014, How Many HIV Infections May Be Averted by Targeting Primary Infection in Men Who Have Sex With Men? Quantification of Changes in Transmission-Risk Behavior, Using an Individual-Based Model, JOURNAL OF INFECTIOUS DISEASES, Vol: 210, Pages: S594-S599, ISSN: 0022-1899

JOURNAL ARTICLE

Thornhill J, Inshaw J, Oomeer S, Kaleebu P, Cooper D, Ramjee G, Schechter M, Tambussi G, Fox J, Maria Miro J, Weber J, Babiker A, Porter K, Fidler Set al., 2014, Enhanced normalisation of CD4/CD8 ratio with early antiretroviral therapy in primary HIV infection, JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, Vol: 17, Pages: 2-2, ISSN: 1758-2652

JOURNAL ARTICLE

, 2014, Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries., AIDS, Vol: 28, Pages: 2461-2473

BACKGROUND: There is little information on the incidence of AIDS-defining events which have been reported in the literature to be associated with immune reconstitution inflammatory syndrome (IRIS) after combined antiretroviral therapy (cART) initiation. These events include tuberculosis, mycobacterium avium complex (MAC), cytomegalovirus (CMV) retinitis, progressive multifocal leukoencephalopathy (PML), herpes simplex virus (HSV), Kaposi sarcoma, non-Hodgkin lymphoma (NHL), cryptococcosis and candidiasis. METHODS: We identified individuals in the HIV-CAUSAL Collaboration, which includes data from six European countries and the US, who were HIV-positive between 1996 and 2013, antiretroviral therapy naive, aged at least 18 years, had CD4 cell count and HIV-RNA measurements and had been AIDS-free for at least 1 month between those measurements and the start of follow-up. For each AIDS-defining event, we estimated the hazard ratio for no cART versus less than 3 and at least 3 months since cART initiation, adjusting for time-varying CD4 cell count and HIV-RNA via inverse probability weighting. RESULTS: Out of 96 562 eligible individuals (78% men) with median (interquantile range) follow-up of 31 [13,65] months, 55 144 initiated cART. The number of cases varied between 898 for tuberculosis and 113 for PML. Compared with non-cART initiation, the hazard ratio (95% confidence intervals) up to 3 months after cART initiation were 1.21 (0.90-1.63) for tuberculosis, 2.61 (1.05-6.49) for MAC, 1.17 (0.34-4.08) for CMV retinitis, 1.18 (0.62-2.26) for PML, 1.21 (0.83-1.75) for HSV, 1.18 (0.87-1.58) for Kaposi sarcoma, 1.56 (0.82-2.95) for NHL, 1.11 (0.56-2.18) for cryptococcosis and 0.77 (0.40-1.49) for candidiasis. CONCLUSION: With the potential exception of mycobacterial infections, unmasking IRIS does not appear to be a common complication of cART initiation in high-income countries.

JOURNAL ARTICLE

Williams JP, Hurst J, Stoehr W, Robinson N, Brown H, Fisher M, Kinloch S, Cooper D, Schechter M, Tambussi G, Fidler S, Carrington M, Babiker A, Weber J, Koelsch KK, Kelleher AD, Phillips RE, Frater Jet al., 2014, HIV-1 DNA predicts disease progression and post-treatment virological control., ELIFE, Vol: 3, ISSN: 2050-084X

JOURNAL ARTICLE

Hamlyn E, Fidler S, Stoehr W, Cooper DA, Tambussi G, Schechter M, Miro JM, Mcclure M, Weber J, Babiker A, Porter Ket al., 2014, Interleukin-6 and D- dimer levels at seroconversion as predictors of HIV-1 disease progression, AIDS, Vol: 28, Pages: 869-874, ISSN: 0269-9370

JOURNAL ARTICLE

Frater J, Ewings F, Hurst J, Brown H, Robinson N, Fidler S, Babiker A, Weber J, Porter K, Phillips REet al., 2014, HIV-1-specific CD4(+) responses in primary HIV-1 infection predict disease progression, AIDS, Vol: 28, Pages: 699-708, ISSN: 0269-9370

JOURNAL ARTICLE

McKay PF, Cope AV, Mann JFS, Joseph S, Esteban M, Tatoud R, Carter D, Reed SG, Weber J, Shattock RJet al., 2014, Glucopyranosyl Lipid A Adjuvant Significantly Enhances HIV Specific T and B Cell Responses Elicited by a DNA-MVA-Protein Vaccine Regimen, PLOS ONE, Vol: 9, ISSN: 1932-6203

JOURNAL ARTICLE

Lacabaratz C, Wiedemann A, Boucherie C, Richert L, Babiker A, Harari A, Bart P, Weber J, McCormack S, Wolf H, Chene G, Thiebaut R, Pantaleo G, Levy Yet al., 2013, A Phase I/II Trial of Preventive HIV Vaccination with DNA and Poxviral-Vector in Healthy Subjects EV03/ANRS VAC20: Cytokine Production by T Cells, Conference on AIDS Vaccine, Publisher: MARY ANN LIEBERT, INC, Pages: A174-A175, ISSN: 0889-2229

CONFERENCE PAPER

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: respub-action=search.html&id=00104515&limit=30&person=true